文献速递冠心病

动脉粥样硬化性心血管疾病抗血小板治疗:2026 ACC 科学声明

Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology.
PubMed 文献 · J Am Coll Cardiol · 2026-06-30

该科学声明系统回顾了抗血小板药物在动脉粥样硬化性心血管疾病管理中的现有证据。阿司匹林仍是最广泛使用的抗血小板药,但近期数据不支持在未经选择的人群中常规用于一级预防。声明比较了现行临床实践指南推荐,总结了关键试验,并讨论了高出血风险、外科手术及不同 ASCVD 表型等情况下的用药考虑。

要点

  • 阿司匹林一级预防应仅用于缺血风险最高的人群。
  • 双联抗血小板治疗的最佳方案和时长已随支架与药物进展而改变。
  • 缺血与出血风险的平衡需要个体化治疗决策。

核心结论

  • 抗血小板药物仍是预防缺血事件的强有力工具,尤其对急性冠脉综合征患者。
  • 缺血风险与出血风险之间的平衡是持久挑战,需要个体化治疗。

研究设计与样本

  • 美国心脏病学会发布的科学声明,提供抗血小板药物在 ASCVD 管理中的详细证据概述。

主要发现

  • 近期数据不支持在未经选择的人群中常规使用阿司匹林进行 ASCVD 一级预防。
  • 药物洗脱支架、抗血小板药物及双联抗血小板治疗最佳方案与时长研究的发展改变了循证推荐。

关键数值与推荐

  • 阿司匹林仍是最广泛使用的抗血小板药物。
  • 一级预防考虑应仅限缺血风险最高的人群。

临床怎么用

  • 需要比较现行临床实践指南推荐来指导抗血小板药物选择。
  • 高出血风险或接受外科手术的患者需特殊考虑抗血小板治疗。
  • 不同 ASCVD 表型及需要合并使用抗栓药物的患者应有针对性考虑。
  • 应重视长期监测和用药依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antiplatelet medications have been fundamental to the management of atherosclerotic cardiovascular disease (ASCVD); however, recommendations for their use have evolved over the past decade. Aspirin remains the most widely used antiplatelet drug. Recent data do not support a benefit for primary prevention of ASCVD in unselected populations with routine aspirin use; consideration should be reserved for those at highest ischemic risk. Similarly, the evolution of drug-eluting stents, antiplatelet medications, and research on the optimal regimen and duration of dual antiplatelet therapy have altered evidence-based recommendations for use of antiplatelets in managing patients diagnosed with ASCVD. Antiplatelet medications remain powerful tools to prevent ischemic events, particularly for those who have experienced an acute coronary syndrome, but the balance between the risk of ischemia and the risk of bleeding poses a perpetual challenge and requires individualized treatment. This scientific statement provides a detailed overview of current evidence for the use of antiplatelets in the management of ASCVD. This includes a comparison of current clinical practice guideline-based recommendations, summary of pivotal trials, and discussion of antiplatelet use in patients with elevated bleeding risk or those undergoing surgery. Considerations for use of antiplatelets in those with different phenotypes of ASCVD and those with indications for concurrent use of antithrombotic medications, as well as long-term monitoring and adherence, are addressed.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kumbhani, Gibson, Kinlay, et al. Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2026. PMID: 42377293. doi:10.1016/j.jacc.2026.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。